Paoluzzi L - Search Results

1

Development and characterization of a novel CD19CherryLuciferase (CD19CL) transgenic mouse for the preclinical study of B-cell lymphomas.

Scotto L, Kruithof-de Julio M, Paoluzzi L, Kalac M, Marchi E, Buitrago JB, Amengual J, Shen MM, O'Connor OA. Scotto L, et al. Among authors: paoluzzi l. Clin Cancer Res. 2012 Jul 15;18(14):3803-11. doi: 10.1158/1078-0432.CCR-11-2588. Epub 2012 May 15. Clin Cancer Res. 2012. PMID: 22589392

2

Romidepsin and belinostat synergize the antineoplastic effect of bortezomib in mantle cell lymphoma.

Paoluzzi L, Scotto L, Marchi E, Zain J, Seshan VE, O'Connor OA. Paoluzzi L, et al. Clin Cancer Res. 2010 Jan 15;16(2):554-65. doi: 10.1158/1078-0432.CCR-09-1937. Epub 2010 Jan 12. Clin Cancer Res. 2010. PMID: 20068080

3

Mechanistic rationale and clinical evidence for the efficacy of proteasome inhibitors against indolent and mantle cell lymphomas.

Paoluzzi L, O'Connor OA. Paoluzzi L, et al. BioDrugs. 2006;20(1):13-23. doi: 10.2165/00063030-200620010-00002. BioDrugs. 2006. PMID: 16573348 Review.

4

The anti-histaminic cyproheptadine synergizes the antineoplastic activity of bortezomib in mantle cell lymphoma through its effects as a histone deacetylase inhibitor.

Paoluzzi L, Scotto L, Marchi E, Seshan VE, O'Connor OA. Paoluzzi L, et al. Br J Haematol. 2009 Sep;146(6):656-9. doi: 10.1111/j.1365-2141.2009.07797.x. Epub 2009 Jul 8. Br J Haematol. 2009. PMID: 19604235 Free article.

5

Pralatrexate is synergistic with the proteasome inhibitor bortezomib in in vitro and in vivo models of T-cell lymphoid malignancies.

Marchi E, Paoluzzi L, Scotto L, Seshan VE, Zain JM, Zinzani PL, O'Connor OA. Marchi E, et al. Among authors: paoluzzi l. Clin Cancer Res. 2010 Jul 15;16(14):3648-58. doi: 10.1158/1078-0432.CCR-10-0671. Epub 2010 May 25. Clin Cancer Res. 2010. PMID: 20501616

6

The novel kinesin spindle protein (KSP) inhibitor SB-743921 exhibits marked activity in in vivo and in vitro models of aggressive large B-cell lymphoma.

Bongero D, Paoluzzi L, Marchi E, Zullo KM, Neisa R, Mao Y, Escandon R, Wood K, O'Connor OA. Bongero D, et al. Among authors: paoluzzi l. Leuk Lymphoma. 2015;56(10):2945-52. doi: 10.3109/10428194.2015.1020058. Epub 2015 May 14. Leuk Lymphoma. 2015. PMID: 25860245

7

New drugs for the treatment of lymphoma.

Paoluzzi L, Kitagawa Y, Kalac M, Zain J, O'Connor OA. Paoluzzi L, et al. Hematol Oncol Clin North Am. 2008 Oct;22(5):1007-35, x. doi: 10.1016/j.hoc.2008.07.006. Hematol Oncol Clin North Am. 2008. PMID: 18954749 Review.

8

Targeting survival pathways in lymphoma.

Paoluzzi L, O'Connor OA. Paoluzzi L, et al. Adv Exp Med Biol. 2010;687:79-96. Adv Exp Med Biol. 2010. PMID: 20919639 Review.

9

The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies.

Paoluzzi L, Gonen M, Bhagat G, Furman RR, Gardner JR, Scotto L, Gueorguiev VD, Heaney ML, Manova K, O'Connor OA. Paoluzzi L, et al. Blood. 2008 Oct 1;112(7):2906-16. doi: 10.1182/blood-2007-12-130781. Epub 2008 Jun 30. Blood. 2008. PMID: 18591385 Free article.

10

Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma.

Paoluzzi L, Gonen M, Gardner JR, Mastrella J, Yang D, Holmlund J, Sorensen M, Leopold L, Manova K, Marcucci G, Heaney ML, O'Connor OA. Paoluzzi L, et al. Blood. 2008 Jun 1;111(11):5350-8. doi: 10.1182/blood-2007-12-129833. Epub 2008 Feb 21. Blood. 2008. PMID: 18292288 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

27 results

Search Page

Filters